Zanidatamab, a bispecific antibody developed for the treatment of patients with previously-treated HER2 gene-amplified Biliary Tract Cancer (BTC).
Zanidatamab is built on Zymeworks’ Azymetric™ platform binding two non-overlapping epitopes of HER2 known asbiparatopic binding. This results in numerous mechanisms of action including twin HER2 signal blockade, increased binding and removal of HER2 protein from the cell surface, and potent effector function which leads to the encouragement of antitumor activity in patients.
Biliary Tract Cancer (BTC), such as gallbladder cancer and cholangiocarcinoma (bile duct cancer), is related with poor prognosis accounting for 3 per cent of all adult cancers.
Worldwide, more than 210,000 people are diagnosed with Biliary tract cancer (BTC) annually. Moreover patients (>65%) affected with BTC are diagnosed with tumors which cannot be removed by surgically. Inspite of patients undergoing curative surgery, BTC cannot be cured permanently and has a high recurrence rate. Patients with advanced BTC have very few treatment options after experiencing front-line chemotherapy.
HER2 is a well targeted anti-cancer therapy. Tumor cells producing HER2 higher than normal level will grow more quickly and spread to other parts of the body.
U.S. Food and Drug administrator has granted breakthrough therapy designation for HER2-Targeted Bispecific Antibody Zanidatamab in Patients with Biliary Tract Cancer.
